Cowan R J, Watson N E
Semin Nucl Med. 1980 Oct;10(4):335-44. doi: 10.1016/s0001-2998(80)80036-5.
Single photon emission tomographic techniques for evaluation of the brain have as their major advantage the ability to employ readily available radionuclides, such as technetium-99m. With present radiopharmaceuticals, single photon emmision tomography of the brain primarily provides morphological information that may be complimentary to standard gamma camera images. Particular areas of assistance have included detection of basal lesions, delineation of multiplicity of lesions, definition of medial extent of abnormalities, clear separation of skull and intracranial abnormalities, and perhaps improved lesion characterization. Overall, however, the reported improvement in sensitivity has been relatively small. To optimally utilize the tomographic and quantiative capabilities of single emission tomography, new classes of radiopharmaceuticals must be developed that can penetrate the blood-brain barrier and provide information on CNS function and pathophysiology. If such radiopharmaceuticals can be labeled with single emission radionuclides, this technique has the potential to provide critically important information. The ultimate outcome of single emission tomographic techniques for the study of the brain may depend on radiopharmaceutical advances.
用于评估大脑的单光子发射断层扫描技术的主要优势在于能够使用如锝-99m等 readily available 放射性核素。对于目前的放射性药物，大脑的单光子发射断层扫描主要提供形态学信息，这可能对标准伽马相机图像起到补充作用。特别有帮助的领域包括基底病变的检测、病变多样性的描绘、异常内侧范围的界定、颅骨与颅内异常的清晰区分，以及可能改善的病变特征描述。然而总体而言，所报道的灵敏度提高相对较小。为了最佳地利用单发射断层扫描的断层摄影和定量能力，必须开发能够穿透血脑屏障并提供有关中枢神经系统功能和病理生理学信息的新型放射性药物。如果此类放射性药物能够用单发射放射性核素进行标记，那么这项技术就有可能提供至关重要的信息。单发射断层扫描技术用于大脑研究的最终结果可能取决于放射性药物的进展。
